Treatment of Ocular Cancers with p53 Activators (SJ-06-0004)

Technology Name
(St. Jude Reference #)
Treatment of Ocular Cancers with p53 Activators
Description Treatment of ocular cancers, such as retinoblastoma, using activators of the p53 pathway is provided. Compounds which inhibit the effect of MDM2 and MDMX on p53, such as nutlin-3, are identified as useful for activating p53 and treating ocular cancers.
Keywords MDMX, MDM2, p53, retinoblastoma, nutlin
Granted Patents or Published Applications US 8,470,785; 8,614,192
Related Scientific References Laurie, N.A. et al., “Targeting MDM2 and MDMX in retinoblastoma”, Curr. Cancer Drug Targets 7(7): 689-695 (2007); Marine, J.C. et al., “MDMX: from bench to bedside”, J. Cell Science 120(Pt3): 371-378 (2007); Laurie, N.A. et al., “Inactivation of the p53 pathway in retinoblastoma”, Nature 444(7115): 61-66 (2006).
Licensing Opportunities We are currently seeking licensing opportunities in all fields for the development of this technology.

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

Last update: April 2014